
Horizon lowers expectations for Tepezza and adjusts its strategy for the year ahead
One of Horizon Therapeutics’ top sellers isn’t performing as well as expected, CEO Tim Walbert revealed on Wednesday’s Q2 call, leading the pharma company to switch up its strategy.
While Walbert noted a 13% increase in sales last quarter, totaling $876.4 million, the chief executive lowered his full-year expectations for the thyroid eye disease (TED) drug Tepezza. While the drug was initially expected to see a percentage growth in the mid-30s, Walbert now anticipates a sales growth in the high-teens.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 147,300+ biopharma pros reading Endpoints daily — and it's free.